Literature DB >> 18712279

Long-lasting successful cerebral response with sorafenib in advanced renal cell carcinoma.

Francesca Valcamonico1, Vittorio Ferrari, Vito Amoroso, Giovanni Rangoni, Edda Simoncini, Patrizia Marpicati, Lucia Vassalli, Salvatore Grisanti, Giovanni Marini.   

Abstract

We report the case of a 75-year old woman who received sorafenib (Nexavar), Bayer Pharmaceuticals Corporation, West Haven, CT) for a CNS relapse of clear cell renal cell carcinoma. After four months of sorafenib treatment, a brain magnetic resonance imaging showed 95%-volumetric regression of cerebral metastasis. To the best of our knowledge, this is the first almost complete resolution of brain metastases in renal cell carcinoma treated with sorafenib that has been described.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18712279     DOI： 10.1007/s11060-008-9676-4

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


  12 in total

1.  Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.

Authors:  Mark J Ratain; Tim Eisen; Walter M Stadler; Keith T Flaherty; Stan B Kaye; Gary L Rosner; Martin Gore; Apurva A Desai; Amita Patnaik; Henry Q Xiong; Eric Rowinsky; James L Abbruzzese; Chenghua Xia; Ronit Simantov; Brian Schwartz; Peter J O'Dwyer
Journal:  J Clin Oncol       Date:  2006-04-24       Impact factor: 44.544

Review 2.  Renal-cell carcinoma.

Authors:  R J Motzer; N H Bander; D M Nanus
Journal:  N Engl J Med       Date:  1996-09-19       Impact factor: 91.245

3.  Sorafenib in advanced clear-cell renal-cell carcinoma.

Authors:  Bernard Escudier; Tim Eisen; Walter M Stadler; Cezary Szczylik; Stéphane Oudard; Michael Siebels; Sylvie Negrier; Christine Chevreau; Ewa Solska; Apurva A Desai; Frédéric Rolland; Tomasz Demkow; Thomas E Hutson; Martin Gore; Scott Freeman; Brian Schwartz; Minghua Shan; Ronit Simantov; Ronald M Bukowski
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

Review 4.  Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.

Authors:  Dirk Strumberg; Jeffrey W Clark; Ahmad Awada; Malcolm J Moore; Heike Richly; Alain Hendlisz; Hal W Hirte; Joseph P Eder; Heinz-Josef Lenz; Brian Schwartz
Journal:  Oncologist       Date:  2007-04

Review 5.  Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies.

Authors:  Luciano J Costa; Harry A Drabkin
Journal:  Oncologist       Date:  2007-12

Review 6.  Protein kinase inhibitors in the treatment of renal cell carcinoma: sorafenib.

Authors:  S Bracarda; C Caserta; L Sordini; M Rossi; A Hamzay; L Crinò
Journal:  Ann Oncol       Date:  2007-06       Impact factor: 32.976

7.  Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis.

Authors:  Robert C Flanigan; G Mickisch; Richard Sylvester; Cathy Tangen; H Van Poppel; E David Crawford
Journal:  J Urol       Date:  2004-03       Impact factor: 7.450

8.  Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma.

Authors:  Robert J Motzer; Jennifer Bacik; Lawrence H Schwartz; Victor Reuter; Paul Russo; Stephanie Marion; Madhu Mazumdar
Journal:  J Clin Oncol       Date:  2004-02-01       Impact factor: 44.544

Review 9.  Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm.

Authors:  Elizabeth R Gerstner; Robert L Fine
Journal:  J Clin Oncol       Date:  2007-06-01       Impact factor: 44.544

10.  BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.

Authors:  Scott M Wilhelm; Christopher Carter; Liya Tang; Dean Wilkie; Angela McNabola; Hong Rong; Charles Chen; Xiaomei Zhang; Patrick Vincent; Mark McHugh; Yichen Cao; Jaleel Shujath; Susan Gawlak; Deepa Eveleigh; Bruce Rowley; Li Liu; Lila Adnane; Mark Lynch; Daniel Auclair; Ian Taylor; Rich Gedrich; Andrei Voznesensky; Bernd Riedl; Leonard E Post; Gideon Bollag; Pamela A Trail
Journal:  Cancer Res       Date:  2004-10-01       Impact factor: 13.312
View more
  9 in total

1.  The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primates.

Authors:  AeRang Kim; Cindy McCully; Rafael Cruz; Diane E Cole; Elizabeth Fox; Frank M Balis; Brigitte C Widemann
Journal:  Invest New Drugs       Date:  2010-11-12       Impact factor: 3.850

Review 2.  Targeted therapies in renal cell cancer: recent developments in imaging.

Authors:  Astrid A M van der Veldt; Martijn R Meijerink; Alfons J M van den Eertwegh; Epie Boven
Journal:  Target Oncol       Date:  2010-07-14       Impact factor: 4.493

3.  A phase I trial of concurrent sorafenib and stereotactic radiosurgery for patients with brain metastases.

Authors:  Kyle Arneson; Joshua Mondschein; Mark Stavas; Anthony J Cmelak; Albert Attia; Leora Horn; Kenneth Niermann; Igor Puzanov; A Bapsi Chakravarthy; Fen Xia
Journal:  J Neurooncol       Date:  2017-05-09       Impact factor: 4.130

4.  Tyrosine kinase inhibitors ameliorate autoimmune encephalomyelitis in a mouse model of multiple sclerosis.

Authors:  Oliver Crespo; Stacey C Kang; Richard Daneman; Tamsin M Lindstrom; Peggy P Ho; Raymond A Sobel; Lawrence Steinman; William H Robinson
Journal:  J Clin Immunol       Date:  2011-08-17       Impact factor: 8.317

5.  Treatment strategy for metastatic brain tumors from renal cell carcinoma: selection of gamma knife surgery or craniotomy for control of growth and peritumoral edema.

Authors:  Takashi Shuto; Shigeo Matsunaga; Jun Suenaga; Shigeo Inomori; Hideyo Fujino
Journal:  J Neurooncol       Date:  2010-04-20       Impact factor: 4.130

6.  Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters.

Authors:  Shuiying Hu; Zhaoyuan Chen; Ryan Franke; Shelley Orwick; Ming Zhao; Michelle A Rudek; Alex Sparreboom; Sharyn D Baker
Journal:  Clin Cancer Res       Date:  2009-09-22       Impact factor: 12.531

Review 7.  Oral Targeted Therapies and Central Nervous System (CNS) Metastases.

Authors:  Michael P Gabay; Scott M Wirth; Joan M Stachnik; Colleen L Overley; Katie E Long; Linda R Bressler; John L Villano
Journal:  CNS Drugs       Date:  2015-11       Impact factor: 5.749

8.  Successful treatment of a brain-metastasized renal cell carcinoma.

Authors:  M Sami Walid; Kim W Johnston
Journal:  Ger Med Sci       Date:  2009-10-21

9.  Extracerebral metastases determine the outcome of patients with brain metastases from renal cell carcinoma.

Authors:  Ursula M Vogl; Marija Bojic; Wolfgang Lamm; Josa M Frischer; Oskar Pichelmayer; Gero Kramer; Andrea Haitel; Klaus Kitz; Kaan Harmankaya; Christoph C Zielinski; Manuela Schmidinger
Journal:  BMC Cancer       Date:  2010-09-07       Impact factor: 4.430
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.